Mesothelioma.com Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

Linda L. Garland, MD

Dr. Garland
Tucson, AZ

Dr. Linda L. Garland

Director, Clinical Lung Cancer Program

University of Arizona Cancer Center

3838 North Campbell Avenue
Tucson, AZ 85719
520.626.3434

Need Help Contacting This Doctor?

Dr. Linda Garland is a thoracic medical oncologist and translational researcher with expertise in mesothelioma. She currently serves as Director of Clinical Research in Thoracic Oncology and Director of the Clinical Lung Cancer Program at the University of Arizona Cancer Center. Dr. Garland also works as a professor of medicine, specifically on the clinical-scholar track. She previously served for 10 years on the University of Arizona Institutional Review Board. Today, Dr. Garland serves as chair of the University of Arizona Cancer Center Scientific Review Committee.

Dr. Garland has built her career around searching for promising new ways to fight for cancer. Experimental therapeutics is the main focus of her research, particularly related to malignant diseases of the chest. She has developed and led translational clinical trials for novel targeted agents in advanced mesothelioma, as well as lung cancer. Her studies have investigated the efficacy of chemotherapy and focused on developing novel cancer therapies and biomarkers for earlier detection.

Main Specialty: Thoracic Medical Oncology

Other Interests & Specialties: Oncology, hematologic oncology, lung cancer, non-small cell lung cancer, parathyroid cancer, small cell lung cancer, head and neck cancer, squamous cell carcinoma, thyroid cancer and mesothelioma.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Hematology, Chair of the University of Arizona Cancer Center Scientific Review Committee, member of The American College of Chest Physicians Task Force on Women and Girls, Tobacco, & Lung Cancer

Education & Experience:

Publications:
Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology. February 15;10(2):387–391. doi: 10.1097/JTO.0000000000000360

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? The Annals of Thoracic Surgery. January 2019; 107(1):194 - 201. doi: 10.1016/j.athoracsur.2018.07.081

A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. Journal of Thoracic Oncology. March 2011;6(3):598–601. doi: 10.1097/JTO.0b013e318208c83d

Individualizing mesothelioma treatment: small steps into a brighter future. Clinical Lung Cancer. November 2010;11(6):371-3. doi: 10.3816/CLC.2010.n.048

Mesothelioma Clinical Trials by Linda L. Garland, MD

Dr. Garland is associated with the following clinical trials:

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Share
Tweet
Share
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To:

Legal Rights Information Guide Free Guide Request Free Guide Free Mesothelioma Guide Free 2019 Mesothelioma Guide